Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS
Season 14, Episode 38, Oct 31, 11:25 PM
Share
Subscribe
Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.
In today’s episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina.
In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into prostate cancer clinical practice, toxicities and quality-of-life complications associated with this class of agents that health care providers should be aware of and try to mitigate, and the importance of shared decision-making between members of the multidisciplinary team, as well as patients.
In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into prostate cancer clinical practice, toxicities and quality-of-life complications associated with this class of agents that health care providers should be aware of and try to mitigate, and the importance of shared decision-making between members of the multidisciplinary team, as well as patients.